Xenon Pharmaceuticals Inc.
XENE
$58.81
-$0.74-1.24%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 7.50M | 7.50M | 7.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 0.00 | 7.50M | 7.50M | 7.50M |
| Cost of Revenue | 352.49M | 328.25M | 300.94M | 272.71M | 252.63M |
| Gross Profit | -352.49M | -328.25M | -293.44M | -265.21M | -245.13M |
| SG&A Expenses | 89.10M | 84.41M | 79.63M | 75.57M | 72.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 441.59M | 412.66M | 380.57M | 348.28M | 325.62M |
| Operating Income | -441.59M | -412.66M | -373.07M | -340.78M | -318.12M |
| Income Before Tax | -411.14M | -385.15M | -344.89M | -309.70M | -282.60M |
| Income Tax Expenses | -1.94M | -1.98M | 1.02M | -3.37M | -4.37M |
| Earnings from Continuing Operations | -409.20 | -383.17 | -345.91 | -306.33 | -278.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -409.20M | -383.17M | -345.91M | -306.33M | -278.23M |
| EBIT | -441.59M | -412.66M | -373.07M | -340.78M | -318.12M |
| EBITDA | -439.19M | -410.19M | -370.53M | -338.18M | -315.50M |
| EPS Basic | -4.74 | -4.70 | -4.36 | -3.88 | -3.54 |
| Normalized Basic EPS | -2.98 | -2.95 | -2.72 | -2.45 | -2.25 |
| EPS Diluted | -4.74 | -4.70 | -4.36 | -3.88 | -3.54 |
| Normalized Diluted EPS | -2.98 | -2.95 | -2.72 | -2.45 | -2.25 |
| Average Basic Shares Outstanding | 346.33M | 325.67M | 317.02M | 315.28M | 313.95M |
| Average Diluted Shares Outstanding | 346.33M | 325.67M | 317.02M | 315.28M | 313.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |